Loading…
InspireMD, Inc. is projected to decline to $0.824 by 2027, a -6% move from its current price of $0.8795. NSPR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8497 | $0.8794 | $0.9102 | -0.01% |
| May 30 | $0.8376 | $0.8793 | $0.9232 | -0.02% |
| May 31 | $0.8284 | $0.8792 | $0.9332 | -0.03% |
| Jun 1 | $0.8207 | $0.8791 | $0.9418 | -0.04% |
| Jun 2 | $0.8139 | $0.879 | $0.9493 | -0.05% |
| Jun 3 | $0.8079 | $0.8789 | $0.9562 | -0.06% |
| Jun 4 | $0.8024 | $0.8789 | $0.9626 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8024 | $0.8789 | $0.9626 | -0.07% |
| Week 2 | $0.7721 | $0.8782 | $0.9989 | -0.15% |
| Week 3 | $0.7496 | $0.8776 | $1.03 | -0.22% |
| Week 4 | $0.731 | $0.8769 | $1.05 | -0.29% |
| Week 5 | $0.7149 | $0.8763 | $1.07 | -0.37% |
| Week 6 | $0.7006 | $0.8756 | $1.09 | -0.44% |
| Week 7 | $0.6877 | $0.875 | $1.11 | -0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
InspireMD, Inc., a healthcare company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
InspireMD, Inc. is categorized under Healthcare. It markets a portfolio of devices designed for carotid and vascular procedures, supporting its focus on interventional solutions and protection systems.
The description highlights the company’s founding year and its headquarters as part of its corporate profile, framing its regional and international footprint in the medical device sector.
InspireMD, Inc. (NSPR) trades at $0.8795, with a market cap of $41.19M and a rank of 4624. These metrics place the stock among smaller-cap healthcare names.
The stock operates in the Healthcare category and has a 30-day price range of $0.701 to $1.10, reflecting recent volatility within a narrow band around the current price.
Forecasts project a varied near- to long-term path. In 2026 the min was $0.8795, avg $0.8795, max $1.14 with ROI 0 and sentiment NEUTRAL, suggesting a flat near-term trajectory. From 2029 onward, the outlook becomes more bullish, with the average price rising to $1.12 in 2029 and continuing upward to $3.44 by 2050, with a max of $6.99 and a cumulative bullish signal in the later years.
A major floor 35.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.1% away) — a key level to hold.
The nearest ceiling, 53.5% above — a clean break opens room to run.
A major ceiling 110.3% above — clearing it would confirm fresh momentum.
Key NSPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NSPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.972 | Sell | $0.9609 | Sell |
| MA 10 | $1.03 | Sell | $1.01 | Sell |
| MA 20 | $1.10 | Sell | $1.09 | Sell |
| MA 50 | $1.33 | Sell | $1.28 | Sell |
| MA 100 | $1.52 | Sell | $1.48 | Sell |
| MA 200 | $1.86 | Sell | $1.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 23.77 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -177.75 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -23.48 | Sell |
| Bollinger %B (20,2) | -0.08 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.06 | Sell |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 18.01 | Buy |
| Momentum (10) | -0.32 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.93 | Sell |
| ADX (14) | 37.69 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows sentiment is NEUTRAL. RSI14 stands at 20, indicating oversold conditions, while the 50-day simple moving average (SMA50) is $1.33 and the 200-day simple moving average (SMA200) is $1.86.
Support is listed at $0.88 and resistance at $1.35, framing a tight near-term corridor around the current price. The 30-day range spans $0.701 to $1.10, highlighting modest volatility within a narrow band around the current level.
Annualized volatility is high at 70%, underscoring substantial move potential in either direction over time.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.8795 | $0.8795 | $1.14 | 0% | Neutral | |
| $0.637 | $0.824 | $1.14 | -6% | Neutral | |
| $0.6862 | $0.9194 | $1.33 | +5% | Neutral | |
| $0.8085 | $1.12 | $1.67 | +27% | Bullish | |
| $0.7877 | $1.12 | $1.71 | +27% | Bullish | |
| $0.8341 | $1.21 | $1.91 | +38% | Bullish | |
| $0.7794 | $1.16 | $1.87 | +32% | Bullish | |
| $0.6715 | $1.02 | $1.68 | +16% | Neutral | |
| $0.7783 | $1.21 | $2.02 | +37% | Bullish | |
| $0.8664 | $1.37 | $2.33 | +56% | Bullish | |
| $0.9318 | $1.62 | $2.96 | +84% | Bullish | |
| $1.68 | $3.44 | $6.99 | +291% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.8795 | $0.8795 | $1.03 | +0.00% |
| June 2026 | $0.7207 | $0.8512 | $1.03 | -3.22% |
| July 2026 | $0.7297 | $0.8711 | $1.07 | +2.34% |
| August 2026 | $0.7311 | $0.8801 | $1.10 | +1.03% |
| September 2026 | $0.6978 | $0.8458 | $1.07 | -3.90% |
| October 2026 | $0.6908 | $0.8427 | $1.07 | -0.36% |
| November 2026 | $0.7181 | $0.881 | $1.13 | +4.53% |
| December 2026 | $0.7141 | $0.8808 | $1.14 | -0.02% |
Click any year to see its month-by-month NSPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NSPR is projected to trade between $0.8795 and $1.14, averaging $0.8795 — a potential gain of 0% from today's $0.8795. Price action looks broadly range-bound.
InspireMD, Inc.'s 2027 outlook centres on $0.824, within a $0.637 to $1.14 range. That is -6% versus the projected 2026 average. That marks a -6% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, NSPR could reach as high as $1.33, with a base case around $0.9194 and support toward $0.6862 — roughly +5% from $0.8795. Price action looks broadly range-bound.
Expect NSPR to range from $0.8085 to $1.67 through 2029. The $1.12 average target implies a +27% move from current prices. That is up +21% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NSPR price prediction for 2030 points to an average of $1.12 (low $0.7877, high $1.71) — a potential gain of +27% on today's $0.8795. Momentum favours further upside here.
In 2031, NSPR is projected to trade between $0.8341 and $1.91, averaging $1.21 — a potential gain of +38% from today's $0.8795. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
InspireMD, Inc.'s 2032 outlook centres on $1.16, within a $0.7794 to $1.87 range. That is -4% versus the projected 2031 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2033, NSPR could reach as high as $1.68, with a base case around $1.02 and support toward $0.6715 — roughly +16% from $0.8795. A consolidation phase looks the most probable path here.
Expect NSPR to range from $0.7783 to $2.02 through 2034. The $1.21 average target implies a +37% move from current prices. That is up +18% on the projected 2033 average. Momentum favours further upside here.
The NSPR price prediction for 2035 points to an average of $1.37 (low $0.8664, high $2.33) — a potential gain of +56% on today's $0.8795. Buyers look set to stay in control over this stretch.
In 2040, NSPR is projected to trade between $0.9318 and $2.96, averaging $1.62 — a potential gain of +84% from today's $0.8795. That is up +18% on the projected 2035 average. Momentum favours further upside here.
InspireMD, Inc.'s 2050 outlook centres on $3.44, within a $1.68 to $6.99 range. That is up +113% on the projected 2040 average. That marks a +291% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NSPR today (≈ 1,137.009665 NSPR) could be worth
$3,913.28
+$2,913.28 (+291%) by 2050 · US Dollar
Based on the average projected NSPR price of $3.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NSPRwould be worth at today's price.
$1,000 invested in NSPR on May 27, 2025 (≈ 401.606424 NSPR) would be worth
$353.21
-$646.79 (-64.7%) today · 0.35× · US Dollar
Based on a NSPR entry price of $2.49 vs. today's $0.8795.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1 | $879.5 | -12.1% |
| 1 month ago | $1.21 | $726.86 | -27.3% |
| 3 months ago | $1.83 | $480.6 | -51.9% |
| 6 months ago | $1.98 | $444.19 | -55.6% |
| 1 year ago | $2.49 | $353.21 | -64.7% |
| All time (5.0y) ago | $5.31 | $165.63 | -83.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NSPR forecast.
Our base-case forecast reaches $1.80 around 2050.
Implied market cap at $1.80: $84.31M
The year-by-year forecast shows a mix of near-term stability and long-term upside. In 2026 the min, avg, and current price align at $0.8795 with a max of $1.14 and ROI of 0%, indicating a flat start. In 2027 the min drops to $0.637, the avg rises to $0.824, the max to $1.14, with a -6.3% ROI and NEUTRAL sentiment.
From 2028 onward, the path turns more favorable: 2028 min $0.6862, avg $0.9194, max $1.33, ROI 4.5%; 2029 min $0.8085, avg $1.12, max $1.67, ROI 26.9%, sentiment BULLISH; 2030 min $0.7877, avg $1.12, max $1.71, ROI 26.9%, sentiment BULLISH.
The bullish trajectory extends through 2031 (avg $1.21, max $1.91, ROI 37.7%), 2032 (avg $1.16, max $1.87, ROI 31.7%), 2034 (avg $1.21, max $2.02, ROI 37.2%), and 2035 (avg $1.37, max $2.33, ROI 55.8%). By 2040 the forecast shows avg $1.62, max $2.96, ROI 83.6% and by 2050 avg $3.44, max $6.99, ROI 291.3%, with a sustained BULLISH sentiment.
These figures illustrate meaningful upside potential over the long term, tempered by short- to mid-term volatility. While the forecast milestones offer a roadmap for higher price levels, they remain estimates and are not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows min $0.7877, avg $1.12, max $1.71 with ROI 26.9% and sentiment BULLISH.
Forecasts indicate several bullish years, including 2029 (avg $1.12, max $1.67, ROI 26.9%), 2030 (avg $1.12, max $1.71, ROI 26.9%), and 2050 (avg $3.44, max $6.99, ROI 291.3%), but these are estimates and not guaranteed.
Yes. The forecast shows max values reaching $2.33 in 2035, $2.96 in 2040, and $6.99 in 2050, indicating potential to exceed $2 in several years.
Current price is $0.8795. The 30-day range is $0.701 to $1.10.
By 2050 the forecast shows an average price of $3.44 with a maximum of $6.99 and ROI of 291.3%, supported by a bullish sentiment.
InspireMD, Inc. Community Discussion
0Share your InspireMD, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.